|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ABCC2 |
Gene summary for ABCC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ABCC2 | Gene ID | 1244 |
| Gene name | ATP binding cassette subfamily C member 2 | |
| Gene Alias | ABC30 | |
| Cytomap | 10q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q92887 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1244 | ABCC2 | NAFLD1 | Human | Liver | NAFLD | 2.40e-12 | 1.09e+00 | -0.04 |
| 1244 | ABCC2 | S43 | Human | Liver | Cirrhotic | 7.08e-07 | -2.57e-01 | -0.0187 |
| 1244 | ABCC2 | HCC1_Meng | Human | Liver | HCC | 1.66e-100 | -2.07e-03 | 0.0246 |
| 1244 | ABCC2 | HCC2_Meng | Human | Liver | HCC | 1.01e-10 | -3.11e-01 | 0.0107 |
| 1244 | ABCC2 | cirrhotic1 | Human | Liver | Cirrhotic | 2.73e-09 | -3.05e-01 | 0.0202 |
| 1244 | ABCC2 | cirrhotic2 | Human | Liver | Cirrhotic | 4.58e-11 | -3.13e-01 | 0.0201 |
| 1244 | ABCC2 | cirrhotic3 | Human | Liver | Cirrhotic | 1.46e-04 | -3.13e-01 | 0.0215 |
| 1244 | ABCC2 | HCC1 | Human | Liver | HCC | 1.35e-17 | 4.56e+00 | 0.5336 |
| 1244 | ABCC2 | HCC2 | Human | Liver | HCC | 4.19e-37 | 5.72e+00 | 0.5341 |
| 1244 | ABCC2 | HCC5 | Human | Liver | HCC | 1.62e-05 | 3.32e+00 | 0.4932 |
| 1244 | ABCC2 | Pt13.a | Human | Liver | HCC | 3.24e-04 | -2.26e-01 | 0.021 |
| 1244 | ABCC2 | Pt13.b | Human | Liver | HCC | 3.44e-05 | -2.15e-01 | 0.0251 |
| 1244 | ABCC2 | Pt14.d | Human | Liver | HCC | 1.45e-03 | -2.25e-01 | 0.0143 |
| 1244 | ABCC2 | S014 | Human | Liver | HCC | 3.37e-21 | 1.07e+00 | 0.2254 |
| 1244 | ABCC2 | S015 | Human | Liver | HCC | 1.11e-25 | 1.57e+00 | 0.2375 |
| 1244 | ABCC2 | S016 | Human | Liver | HCC | 3.77e-29 | 1.17e+00 | 0.2243 |
| 1244 | ABCC2 | S027 | Human | Liver | HCC | 6.64e-06 | 1.16e+00 | 0.2446 |
| 1244 | ABCC2 | S028 | Human | Liver | HCC | 1.41e-22 | 1.23e+00 | 0.2503 |
| 1244 | ABCC2 | S029 | Human | Liver | HCC | 1.17e-25 | 1.63e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
| GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
| GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
| GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
| GO:00485457 | Liver | NAFLD | response to steroid hormone | 75/1882 | 339/18723 | 3.44e-11 | 1.12e-08 | 75 |
| GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
| GO:00713836 | Liver | NAFLD | cellular response to steroid hormone stimulus | 48/1882 | 204/18723 | 1.50e-08 | 1.83e-06 | 48 |
| GO:00434346 | Liver | NAFLD | response to peptide hormone | 76/1882 | 414/18723 | 1.51e-07 | 1.09e-05 | 76 |
| GO:00513846 | Liver | NAFLD | response to glucocorticoid | 36/1882 | 148/18723 | 3.88e-07 | 2.52e-05 | 36 |
| GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
| GO:00069797 | Liver | NAFLD | response to oxidative stress | 78/1882 | 446/18723 | 7.85e-07 | 4.29e-05 | 78 |
| GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
| GO:00319606 | Liver | NAFLD | response to corticosteroid | 37/1882 | 167/18723 | 3.03e-06 | 1.23e-04 | 37 |
| GO:00713854 | Liver | NAFLD | cellular response to glucocorticoid stimulus | 17/1882 | 56/18723 | 2.17e-05 | 6.02e-04 | 17 |
| GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
| GO:00100387 | Liver | NAFLD | response to metal ion | 62/1882 | 373/18723 | 5.05e-05 | 1.19e-03 | 62 |
| GO:0015850 | Liver | NAFLD | organic hydroxy compound transport | 50/1882 | 284/18723 | 6.01e-05 | 1.32e-03 | 50 |
| GO:00715493 | Liver | NAFLD | cellular response to dexamethasone stimulus | 11/1882 | 29/18723 | 6.39e-05 | 1.39e-03 | 11 |
| GO:00715483 | Liver | NAFLD | response to dexamethasone | 13/1882 | 39/18723 | 6.78e-05 | 1.45e-03 | 13 |
| GO:00713844 | Liver | NAFLD | cellular response to corticosteroid stimulus | 17/1882 | 61/18723 | 7.31e-05 | 1.52e-03 | 17 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa02010 | Liver | NAFLD | ABC transporters | 16/1043 | 45/8465 | 4.97e-05 | 1.16e-03 | 9.37e-04 | 16 |
| hsa049762 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
| hsa020101 | Liver | NAFLD | ABC transporters | 16/1043 | 45/8465 | 4.97e-05 | 1.16e-03 | 9.37e-04 | 16 |
| hsa0497611 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
| hsa015244 | Liver | Cirrhotic | Platinum drug resistance | 34/2530 | 73/8465 | 1.86e-03 | 8.37e-03 | 5.16e-03 | 34 |
| hsa0152411 | Liver | Cirrhotic | Platinum drug resistance | 34/2530 | 73/8465 | 1.86e-03 | 8.37e-03 | 5.16e-03 | 34 |
| hsa015242 | Liver | HCC | Platinum drug resistance | 52/4020 | 73/8465 | 3.14e-05 | 1.88e-04 | 1.04e-04 | 52 |
| hsa020102 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
| hsa015243 | Liver | HCC | Platinum drug resistance | 52/4020 | 73/8465 | 3.14e-05 | 1.88e-04 | 1.04e-04 | 52 |
| hsa020103 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ABCC2 | SNV | Missense_Mutation | c.1815N>C | p.Gln605His | p.Q605H | Q92887 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| ABCC2 | SNV | Missense_Mutation | rs748245551 | c.412N>A | p.Leu138Ile | p.L138I | Q92887 | protein_coding | tolerated(0.11) | benign(0.266) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ABCC2 | SNV | Missense_Mutation | rs754646220 | c.4285N>A | p.Glu1429Lys | p.E1429K | Q92887 | protein_coding | deleterious(0.02) | probably_damaging(0.916) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ABCC2 | SNV | Missense_Mutation | rs759540575 | c.4585N>C | p.Tyr1529His | p.Y1529H | Q92887 | protein_coding | deleterious(0.05) | possibly_damaging(0.778) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ABCC2 | SNV | Missense_Mutation | rs754646220 | c.4285N>A | p.Glu1429Lys | p.E1429K | Q92887 | protein_coding | deleterious(0.02) | probably_damaging(0.916) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ABCC2 | SNV | Missense_Mutation | rs377550597 | c.3436N>T | p.Arg1146Cys | p.R1146C | Q92887 | protein_coding | deleterious(0.05) | probably_damaging(1) | TCGA-AR-A0U3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| ABCC2 | SNV | Missense_Mutation | c.1590G>C | p.Lys530Asn | p.K530N | Q92887 | protein_coding | tolerated(0.37) | benign(0.093) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| ABCC2 | SNV | Missense_Mutation | rs751269660 | c.3806T>G | p.Val1269Gly | p.V1269G | Q92887 | protein_coding | deleterious(0) | possibly_damaging(0.703) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| ABCC2 | SNV | Missense_Mutation | novel | c.2008A>G | p.Ile670Val | p.I670V | Q92887 | protein_coding | tolerated(1) | benign(0) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| ABCC2 | SNV | Missense_Mutation | c.3610A>T | p.Asn1204Tyr | p.N1204Y | Q92887 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | tamoxifen | TAMOXIFEN | ||
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | doxorubicin | DOXORUBICIN | 16330681 | |
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | mycophenolic acid | 25163792,28624888 | ||
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | SN-38 | 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ||
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | Drugs For Treatment Of Tuberculosis | 31648372 | ||
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | deferasirox | DEFERASIROX | 25348619,26403473 | |
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | CEFACLOR | CEFACLOR | 22166395 | |
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | ritonavir | RITONAVIR | 26287941 | |
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | pravastatin | PRAVASTATIN | 17047488 | |
| 1244 | ABCC2 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE | methotrexate | METHOTREXATE | 27217051,24241962,29791011,23069858,25502615,23222202,21317831,18381794 |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |